Electrochemotherapy is the combined use of a chemotherapeutic agent and pulsed electric fields. Electrical treatment causes an increase in cell membrane permeability which allows the chemotherapeutic agent to more freely enter the tumor cells. Electrochemotherapy has been under development in clinical trials. This study focused on determining the applicability of electrochemotherapy for treating soft tissue sarcoma using an animal model bearing human sarcomas. The antitumor effects of several concentrations of cisplatin, bleomycin, doxorubicin, and netropsin as single agents delivered with electric pulses were investigated based on post-treatment tumor volumes and histology. Electrochemotherapy treatment resulted in 5% to 88.9% durable complete responses; ECT that employed bleomycin resulted in the highest antitumor effects. This indicates the feasibility of electrochemotherapy as a modality for limb preserving treatments for sarcoma of the extremities.
LevineE. A., TripponM., GuptaDas T. K.Preoperative multimodality treatment for soft-tissue sarcomas. Cancer71, 3685–9 (1993).
2.
YangJ. C., GlatsteinE. J., RosenbergS. A., and AntmanK. H.Sarcomas of Soft Tissues, in Cancer. Principles and practice of oncology, ed. 5. pp 1437–88. Eds., DevitaV. T.Jr., HellmanS., RosenbergS. A., J. B. Lippincott Co., Philadelphia (1993).
3.
LawrenceW.Jr. Operative management of soft-tissue sarcomas: Impact of anatomic site. Semin. Surg. Oncol.10, 340–6 (1994).
4.
ChoongP. E., PetersenI. A., NascimentoA. G., and SimF. H.Is radiotherapy important for low-grade soft tissue sarcoma of the extremity?Clinical Orthopaedics & Related Research387, 191–9 (2001).
5.
YangJ. C. and RosenbergS. A.Surgery for adult patients with soft tissue sarcomas. Semin. Oncol.16, 289–96 (1989).
6.
PistersP. W. T., HarrisonL. B., WoodruffJ. M., GaynorJ. J., and BrennanM. F.A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J. Clin. Oncol.12, 1150–5 (1994).
7.
RosenbergS. A., KentH., CostaJ., WebberB. L., YoungR., ChabnerB., BakerA. R., BrennanM. F., ChretienP. B., CohenM. H., deMossE. V., SearsH. F., SeippC., and SimonR.Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surg.84, 62–9 (1978).
8.
MirL. M., BanounH., and PaolettiC.Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: Direct acess to the cytosol. Exp. Cell Res.175, 15–25 (1998).
9.
OrlowskiS., BelehradekJ.Jr., PaolettiC., and MirL. M.Transient electropermeabilization of cells in culture. Biochem. Pharmacol.37, 4727–33 (1988).
10.
HellerR., JaroszeskiM., Leo-MessinaJ., PerrottR., Van VoorhisN., ReintgenD.Treatment of B16 melanoma with the combination of electroporation and chemotherapy. Bioelectrochem. Bioenerget.36, 83–7 (1995).
11.
MirL. M., OrlowskiS., BelehradekJ.Jr., and PaolettiC.Electrochemotherapy potentiation of antitumor effect of bleomycin by local electric pulses. Eur. J. Cancer27, 68–72 (1991).
12.
SersaG., CemazarM., and MiklavcicD.Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum (II) in mice. Cancer Res.55, 3450–5 (1995).
13.
KanesadaH.Anticancer effect of high voltage pulses combined with concentration dependent anticancer drugs on lewis lung carcinoma, in vivo. J. Jpn. Soc. Cancer Ther.25, 2640–8 (1990).
14.
BelehradekJ.Jr., OrlowskiS., PoddevinB., PaolettiC., and MirL. M.Electrochemotherapy of spontaneous mammary tumors in mice. Eur J. Cancer27, 73–6 (1991).
15.
OkinoM., TomieH., KanesadaH., MarumotoM., MoritaN., EsatoK.Induction of tumor specific selective toxicity in electrical impulse chemotherapy-analysis of dose response curve. Oncologia24, 71–9 (1991).
16.
SalfordL. G., PerssonB. R. R., BrunA., CebergC. P., KongstadP. C. H., and MirL. M.A new brain tumor therapy combining bleomycin with in vivo electropermeabilization. Biochem. Biophys. Res. Comm.194, 938–43 (1993).
17.
HellerR., JaroszeskiM., MessinaJ., PerrottR., Van VoorhisN., and GilbertR.Treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res.7, 10–8 (1997).
18.
JaroszeskiM. J., MessinaJ., PerrottR., Van VoorhisN., GilbertR., and HellerR.Effectiveness of treating B16 melanoma with multiple treatment electrochemotherapy. Melanoma Res.6, 427–33 (1996).
19.
GilbertR. A., JaroszeskiM. J., and HellerR.Novel electrode designs for electrochemotherapy. Biochem. Biophys. Acta1334, 9–14 (1997).
20.
JaroszeskiM. J., GilbertR. A., and HellerR.In vivo antitumor effects of electrochemotherapy in a hepatoma model. Biochem. Biophys. Acta1334, 15–8 (1997).
21.
HofmannG. A., DevS. B., and NandaG. S.Electrochemotherapy: Transition from laboratory to the clinic. IEEE Engineering in Medicine and Biology15, 124–32 (1996).
22.
HellerR., JaroszeskiM. J., ReintgenD. S., PuleoC. A., DeContiR. C., GilbertR. A., and GlassL. F.Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer83, 148–57 (1998).
23.
HellerR., JaroszeskiM. J., GlassL. F., MessinaJ. L., RapaportD. P., DeContiR. C.Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer77, 964–71 (1996).
24.
RudolfZ., StabucB., CemazarM., MiklavcicD., VodovnikL., and SersaG.Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol. Oncol.29, 229–35 (1995).
25.
GlassL. F., FenskeN. A., JaroszeskiM. J., PerrottR., HarveyD. T., ReintgenD. S.Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J. Am. Acad. Dermatol.34, 82–6 (1996).
26.
MirL. M., BelehradekM., DomengeC., OrlowskiS., PoddevinJ.Jr., SchwabG.Electrochemotherapy, a novel antitumor treatment: First clinical trial. C. R. Acad. Sci. III313, 613–8 (1991).
27.
BelehradekM., DomengeC., LuboinnskiB., OrlowskiS., BelehradekJ., and MirL. M.Electrochemotherapy, a new antitumor treatment. Cancer72, 3694–700 (1993).
JaroszeskiM. J., GilbertR., and HellerR.Electrochemotherapy: An emerging drug delivery method for the treatment of cancer. Advanced Drug Delivery Reviews26, 185–97 (1997).
30.
CasperE. S., GaynorJ. J., HarrisonL. B., PanicekD. M., HajduS. I., and BrennanM. F.Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer73, 1644–1651 (1994).
31.
WilsonR. E., WoodW. C., LernerH. L., AntmanK., AmatoD., CorsonJ. M., ProppeK., HarmonD., CareyR., GreenbergerJ., and SuitH.Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch. Surg.121, 1354–1359 (1986).
32.
HyacintheM., JaroszeskiM., DangV. V., CoppolaD., KarlR. C., GilbertR., and HellerR.Electrically enhanced drug delivery for the treatment of human sarcoma in nude rats. Cancer85, 409–417, (1999).
33.
PendasS., JaroszeskiM. J., GilbertR., HyacintheM., DangV., HickeyJ., PottingerC., IllingworthP., and HellerR.Direct Delivery of chemotherapeutic agents for the treatment of hepatomas and sarcomas in rat models. Radiologic Oncology32, 53–64 (1998).
34.
SersaG., StabucB., CemazarM., JancarB., MiklavcicD., RudolfZ.Electrochemotherapy with cisplatin: Potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. European J. Cancer34, 1212–8 (1998).
35.
GehlJ., SkovsgaardT., and MirL. M.Enhancement of cytotoxicicity by electropermeabilization: An improved method for screening drugs. Anti-Cancer Drugs9, 319–25 (1998).
36.
JaroszeskiM. J., DangV., PottingerC., HickeyJ., GilbertR., and HellerR.Toxicity of anticancer agents mediated by electroporation in vitro. Anti-Cancer Drugs11, 201–8 (2000).
37.
HellerL., PottingerC., JaroszeskiM. J., GilbertR., and HellerR.In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long term antitumour immunity. Melanoma Research10, 577–83 (2000).
38.
MirL. M., OrlowskiS., PoddevinB., BelehradedJ.Jr., Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host's defenses. Eur. Cytokine Netw.3, 331–4 (1992).
39.
MirL. M., RothC., OrlowskiS., Quintin-ColonnaR., FradeliziD., BelehradekJ.Jr.,Systemic Antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2 J. Immunol.17, 30–8 (1995).
40.
HellerR., CoppolaD., PottingerC., GilbertR., and JaroszeskiM. J.Effect of electrochemotherapy on muscle and skin. Technology in Cancer Research and Treatment5, 385–392 (2002).
41.
McGrathD. C., SloanD. A., DenadyD. E.Adjuvant therapy of soft-tissue sarcomas. Clin. Plas. Surgery22, 21–9 (1995).
42.
AmatoD. A., BordenE. C., ShirakiM., EnterlineH. T., RosenbaumC., DavisH. L., PaulA. R., StevensC. M., and LernerH. J.Evaluation of Bleomycin, Chlorozotocin, MGBG, and Bruceantin in patients with advanced soft-tissue sarcoma, bone sarcomas, or mesothelioma. Invest. New Drugs3, 397–401 (1985).
